Gorecka-Tisera A M, McCulloch M A, Borle A B
Immunopharmacology. 1986 Aug;12(1):59-67. doi: 10.1016/0162-3109(86)90052-4.
The effects of several calmodulin antagonists on the activation of RAW-264 macrophage-like cells for tumor cell killing were investigated. At concentrations ranging from 5 X 10(-8) to 5 X 10(-7) M, calmidazolium, trifluoperazine, chlorprothixene, chlorpromazine and W-13 inhibited the development of cytolytic activity, evoked in RAW-264 by treatment with lymphokine and lipopolysaccharide, in a dose-dependent manner. Since the order of the potency of these drugs against the activation of RAW-264 cells was much the same as their ability to inhibit calmodulin-dependent phosphodiestherase activity: calmidazolium greater than trifluoperazine greater than chlorprothixene greater than chlorpromazine greater than W-13, and because W-12, a nonactive analog of W-13, failed to inhibit the process of activation, we believe that the development of cytolytic activity in RAW-264 cells may be dependent on calmodulin. At micromolar concentrations, calmodulin antagonists (except calmidazolium) enhanced the process of activation. The enhancement of cytolytic activity was neither the result of the toxicity of these drugs nor related to their effects on intracellular calcium. It was entirely dependent on the presence of stimulants but occurred independently from the stage of macrophage activation, and most likely was due to the nonspecific interference of these agents with calmodulin-independent processes.
研究了几种钙调蛋白拮抗剂对RAW-264巨噬细胞样细胞激活以杀伤肿瘤细胞的影响。在5×10⁻⁸至5×10⁻⁷M的浓度范围内,氯咪唑、三氟拉嗪、氯丙硫蒽、氯丙嗪和W-13以剂量依赖的方式抑制了RAW-264细胞经淋巴因子和脂多糖处理后诱发的溶细胞活性的发展。由于这些药物对RAW-264细胞激活的效力顺序与其抑制钙调蛋白依赖性磷酸二酯酶活性的能力大致相同:氯咪唑>三氟拉嗪>氯丙硫蒽>氯丙嗪>W-13,并且由于W-13的无活性类似物W-12未能抑制激活过程,我们认为RAW-264细胞中溶细胞活性的发展可能依赖于钙调蛋白。在微摩尔浓度下,钙调蛋白拮抗剂(氯咪唑除外)增强了激活过程。溶细胞活性的增强既不是这些药物毒性的结果,也与它们对细胞内钙的影响无关。它完全依赖于刺激物的存在,但独立于巨噬细胞激活阶段发生,最可能是由于这些药物对不依赖钙调蛋白的过程的非特异性干扰。